You are here

  • Home
  • Archive
  • Volume 1, Issue 1
  • The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region

Article Text

Article menu

Download PDFPDF

Rheumatoid arthritis
Extended report
The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region
  1. X Mariette1,
  2. J Vencovsky2,
  3. O Lortholary3,
  4. J Gomez-Reino4,
  5. M de Longueville5,
  6. P Ralston6,
  7. M Weinblatt7 and
  8. R van Vollenhoven8
  1. 1Université Paris-Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM U1184, Le Kremlin Bicêtre, France
  2. 2Department of Rheumatology, Institute of Rheumatology, Charles University, Prague, Czech Republic
  3. 3IHU Imagine, Université Paris Descartes, Centre d'Infectiologie Necker Pasteur, Hôpital Necker Enfants Malades, AP-HP, Paris, France
  4. 4Universidad de Santiago de Compostela, Santiago, Spain
  5. 5UCB Pharma, Brussels, Belgium
  6. 6GP Ltd, London, UK
  7. 7Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, USA
  8. 8Karolinska Institute, Stockholm, Sweden
  1. Correspondence to Professor Xavier Mariette; xavier.mariette{at}bct.aphp.fr

Abstract

Objectives We report the incidence of tuberculosis (TB) across certolizumab pegol (CZP) clinical trials in rheumatoid arthritis (RA), psoriasis, psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), before and after the introduction of stricter TB screening.

Methods TB incidence rates (IRs) were assessed and stratified according to screening guidelines used at the time of CZP trials. Before 2007 (original trials), purified protein derivative (PPD) tuberculin skin test positivity varied according to local standards (induration ≥5 up to ≥20 mm). Since 2007, all CZP trial protocols have been amended, including trials spanning (intermediate) and initiated after 2007 (current), mandating that any patient with PPD≥5 mm receives treatment for latent TB infection (LTBI). All cases of suspected TB or PPD≥5 mm, in pooled data from 5402 CZP patients across all CZP trials up to 2012, underwent blinded central review by independent experts.

Results 44 TB cases were confirmed in pooled CZP RA trials (IR 0.47/100PY, patient-years) with no cases in Japanese RA trials (J-RAPID, HIKARI). Single TB cases were confirmed in psoriasis and axSpA trials (RAPID-axSpA), and no cases in the PsA trial (RAPID-PsA). IR of TB was 0.51/100PY across original or intermediate RA trials and 0.18/100PY in current trials. The majority of TB cases in RA occurred in Eastern (IR 1.02/100PY) and Central Europe (IR 0.58/100PY). Of 242/370 PPD≥5 mm patients who received 9 months isoniazid (INH) treatment for latent TB infection (LTBI), none developed TB, versus 7.8% of 128 untreated PPD≥5 mm patients.

Conclusions Implementation of more stringent LTBI screening, plus treatment for LTBI, reduced the IR of TB, even when INH was administered after starting CZP therapy.

  • Tuberculosis
  • Anti-TNF
  • Autoimmune Diseases

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/rmdopen-2014-000044

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text